Cypherpunk Technologies (NASDAQ:CYPH) Announces Quarterly Earnings Results

Cypherpunk Technologies (NASDAQ:CYPH) announced its quarterly earnings data on Monday. The company reported $0.92 earnings per share for the quarter, FiscalAI reports.

Cypherpunk Technologies Stock Performance

Shares of CYPH opened at $0.79 on Wednesday. The firm has a market capitalization of $32.89 million, a P/E ratio of 11.34 and a beta of -0.16. Cypherpunk Technologies has a 52 week low of $0.22 and a 52 week high of $3.70. The stock has a 50 day moving average price of $0.77 and a two-hundred day moving average price of $0.86.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CYPH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cypherpunk Technologies in a research report on Thursday, January 22nd. Wall Street Zen upgraded Cypherpunk Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, November 25th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. purchased a new stake in Cypherpunk Technologies in the 4th quarter valued at $2,172,000. Acadian Asset Management LLC grew its stake in shares of Cypherpunk Technologies by 470.4% in the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock worth $389,000 after acquiring an additional 1,056,047 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $615,000. State Street Corp bought a new position in shares of Cypherpunk Technologies during the fourth quarter valued at about $163,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cypherpunk Technologies during the fourth quarter valued at about $121,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.